Tissue or nerve injury can dramatically alter the transmission of sensory stimuli by spinal cord neurons, so that a light touch produces pain. The discovery that peptide products of prepronociceptin processing either facilitate or inhibit these mechanisms suggests novel approaches to treating these conditions. Address: Departments of Anatomy and Physiology and the W
Although morphine and other opioids are very effective in the treatment of pain produced by tissue injury, such as postoperative pain, the 'neuropathic' pain associated with nerve injury is often unresponsive to opioids [1] . There is now considerable evidence that neuropathic pain results from a prolonged central sensitization or hyperexcitability of dorsal horn neurons in the spinal cord, which enhances the transmission of 'pain' messages. When this occurs, patients and animals experience allodynia, in which a normally non-noxious stimulus such as a light touch evokes pain, and/or hyperalgesia, in which normally painful (noxious) stimuli produce an exaggerated pain response. Studies of the neurochemical basis of this central sensitization have implicated a variety of mediators, including glutamate acting at N-methyl-D-aspartic acid (NMDA) receptors. In many respects, the development of these long-lasting changes in the spinal cord are comparable to the mechanisms that govern synaptic plasticity in the cortex and hippocampus.
More recently, attention has focused on the contribution of specific peptide neurotransmitters to the development of allodynia and hyperalgesia. Nociceptin, a 17 amino-acid peptide that is an endogenous ligand for the opioid-like receptor ORL1, was found to increase pain responses in mice [2] . Specifically, when nociceptin was injected at low doses intrathecally, that is into the cerebrospinal fluid of the spinal cord, it produced allodynia and hyperalgesia. Because nociceptin, like opioids, increases a K + conductance and decreases a Ca 2+ conductance, this result was surprising, particularly so because ORL1 resembles the µ, δ and κ opioid receptors, which bind analgesia-producing opioids such as morphine. In fact, under some conditions, nociceptin is analgesic. Apparently, the route of administration, dose and state of the animal are critical variables that determine whether nociceptin inhibits or facilitates the transmission of pain messages [3] . The pronociceptive -pain-enhancing -nature of nociceptin was especially provocative because it raised the possibility that this molecule comes into play in the clinical setting of allodynia, and indeed these initial studies have led to some exciting new findings that we describe below.
Okuda-Asitaka et al. [4] have recently found that the nociceptin precursor, prepronociceptin, is also processed to produce peptides that counteract the effects of nociceptin. Their studies identified several new peptide products of prepronociceptin. The most interesting of these, bPNP-3 or nocistatin, was found to block the allodynia and hyperalgesia produced by intrathecal injection of low doses of nociceptin. Nocistatin also reversed the allodynia produced by prostaglandin E 2 (PGE 2 ), but it did not affect nociceptive thresholds when injected by itself. These results indicate that, although nocistatin may regulate allodynic states of differing etiologies, it is not an analgesic; unlike morphine, nocistatin does not raise pain thresholds ( Figure 1 ). In addition to identifying another peptide, bPNP-4, that countered the hyperalgesic action of nociceptin but not its allodynia-producing properties, the authors identified the requisite sequence for the anti-allodynic action of nocistatin. They also showed that injection of an anti-nocistatin antibody further reduced the dose of nociceptin required to produce allodynia. Taken together, these results
Figure 1
The relationship between stimulus intensity and pain, showing how injury and different drugs shift the stimulus-response functions. Two fundamental questions emerge from these initial observations. First, what is the mechanism of nocistatininduced reversal of allodynia? And second, does nocistatin reverse tissue or nerve injury-induced allodynia? Because nociceptin, which lowers the pain threshold, and nocistatin, which normalizes the pain threshold, are synthesized in the same neurons, the key to understanding the allodynic/antiallodynic effects of these peptides is to identify their target receptors and to determine their cellular distribution in the dorsal horn (Figure 2 ). Nociceptin [5] and nocistatin [4] are both expressed in lamina II of the dorsal horn. The ORL1 receptor is also expressed in this region [6] , but because it is also found in dorsal root ganglion cells, it is likely that nociceptin acts, at least in part, upon the presynaptic terminals of primary afferents [2] (Figure 2 ). Importantly, Okuda-Asitaka et al. [4] demonstrated that nocistatin binds a receptor that is distinct from that of nociceptin, but the identity of the nocistatin receptor is not yet established. Without this information one cannot determine whether the ORL1 and nocistatin receptors are expressed in the same or different neurons. The cellular location of the ORL1 and the nocistatin receptors is of particular interest, because we recently demonstrated that mice with a deletion of the gene that encodes the gamma isoform of protein kinase C (PKCγ) do not develop nerveinjury allodynia [7] . Because the neurons that express PKCγ are restricted to a subpopulation of interneurons in the inner part of lamina II of the dorsal horn (Figure 2) , it is possible that nociceptin induces allodynia via circuits that involve the PKCγ-containing interneurons.
What about the possible contribution of these molecules in clinically relevant conditions of allodynia and hyperalgesia?
To address these questions, it will be important to study the action of nociceptin and nocistatin in the setting of injury, when pain thresholds are pathophysiologically lowered. Does the level of nociceptin increase when there is tissue or nerve injury-induced allodynia? Do the concentrations correspond to those that induce allodynia and anti-allodynia when injected intrathecally? Can nocistatin block these changes? Okuda-Asitaka et al. [4] established that nocistatin is present in vivo, but they only measured levels in normal animals. Some indication that significant changes occur comes from the studies of Andoh et al. [8] , who found that persistent inflammation induced an increase in the level of prepronociceptin mRNA in the dorsal root ganglion -the cell bodies of primary afferent fibers that transmit pain messages. Because prepronociceptin mRNA is not detectable in the dorsal root ganglion of normal animals, this finding indicates that this gene is subject to regulation after injury. Interestingly, the peak of the inflammation-induced increase in prepronociceptin mRNA occurred before the onset of allodynia; if differential processing occurs such that the main prepronociceptin-derived peptide produced during the early stages of inflammation is nocistatin, it may contribute to the absence of allodynia at this time.
The fact that nociceptin produces antinociception at higher doses considerably complicates the analysis of its contribution to pain in the setting of injury. For example, nociceptin has been shown to inhibit the phenomenon of 'wind-up', a gradual increase in the firing of dorsal horn neurons that results from repetitive activation of small diameter, unmyelinated C-fibers [9] . This implies that nociceptin can decrease the noxious-stimulus-evoked hyperexcitability of dorsal horn neurons. Nociceptin also reduces noxious-stimulus-induced neurogenic inflammation [10] , and it reduces pain behavior in the setting of injury [11] . From these observations, it is possible that R526 Current Biology, Vol 8 No 15
Figure 2
The major elements of the superficial dorsal horn through which noxious stimuli evoke pain. Nociceptive primary afferent A-δ and C-fibers (red) are activated by noxious stimuli; this information is transmitted to interneurons (purple/green) and projection neurons (blue) of the dorsal horn. The interneurons are concentrated in lamina II and the projection neurons in laminae I and V. As nociceptin is found in lamina II (yellow), its precursor prepronociceptin is probably synthesized by interneurons that act postsynaptically on projection neurons and presynaptically on the terminals of primary afferents, both of which express the ORL1. The PKCγ interneurons (purple) that have been implicated in injuryinduced allodynia are exclusively found in the inner part of lamina II. See text for details. 
ΙΙo
higher concentrations of nociceptin are generated under conditions of injury, resulting in anti-nociceptive rather than pro-nociceptive effects. But will we find, once the nocistatin receptor has been identified, that many of the reported effects of higher doses of nociceptin are, in fact, mediated via the nocistatin receptor? Until antagonists for both receptors are developed, it will be difficult to resolve these issues.
A better understanding of the molecules that underlie injury-induced allodynia and hyperalgesia is critical to the development of new therapies for the treatment of pain. At present, morphine is the drug of choice for severe pain, but there are many problems associated with its use. Tolerance to the analgesic action of morphine develops with longterm use and morphine produces significant deleterious side effects. Furthermore, as illustrated in Figure 1 , morphine produces analgesia by shifting the 'normal pain' stimulus-response curve to the right -this may disrupt the important protective signal that acute pain provides.
We recently demonstrated that mice with a deletion of the gene that encodes the primary afferent tachykininsincluding substance P and neurokinin A -experience the low end of 'normal' pain, but are much less responsive to intense pain stimuli [12] . These animals still developed allodynia in the setting of tissue and nerve injury, however, so tachykinin antagonists may not, by themselves, be useful clinically. The ideal treatment would counteract the leftward shift of the curve that occurs in the setting of injury, without altering normal pain (Figure 1 ). That such therapies can be developed now appears possible. For example, although the PKCγ mutant mice did not develop allodynia after injury, their acute pain thresholds were unchanged. Similarly, although nocistatin blocked nociceptin and PGE 2 -evoked allodynia, it did not alter thresholds when administered alone. If it turns out that nocistatin can block the allodynia that occurs with injury, then these new observations may herald the development of a class of centrally-acting molecules that are selective for injury-associated pain conditions. There are many more questions than answers, but nocistatin may indeed prove to be a new way to spell relief.
